Standards

The PFC Program has established guidelines that provide a system of processes, procedures, and documentation to ensure that Cannabis products (cannabis, cannabis-derived products, hemp, and hemp-derived products) have the strength, composition, purity, and identity they claim to constitute or possess.

Seed to consumption national quality standards now exist for the cannabis and hemp profession thanks to the 2011 collaboration of ASA, the American Herbal Products Association (AHPA), and the American Herbal Pharmacopoeia (AHP). This unique collaboration combines the expertise of ASA, the nation’s largest medical cannabis patient advocacy organization; AHPA, the principal U.S. trade association and voice of the herbal products industry since 1982; and the AHP, an organization that has developed qualitative and therapeutic monographs on Western herbs since 1994. The result is that patients, healthcare providers, lawmakers, regulators, and cannabis and hemp businesses now have the tools they need to ensure reliable, high-quality cannabis, hemp, cannabis-derived, and hemp-derived products.

With the creation of the PFC Standard we have taken the AHPA Recommendations for Regulators and the AHP Cannabis Monograph and added provisions for hemp operators based on the United States Department of Agriculture Hemp Interim Final Rule. The PFC Standard is designed to help businesses become compliant with not only State cannabis requirements but also the requirements of Good Agricultural (Collection) Practices, Good Manufacturing Practices, and Good Laboratory Practices in order to be compliant with any potential Federal requirements that may be put into place.

Public Comment Period

At this time we are opening up the PFC Standard to public comment for 4 weeks. At the end of the public comment period all comments will be reviewed by the PFC Review Board for acceptance or rejection. By making the Standard open for public comment we want to convey our commitment to creating a successful cannabis and hemp profession that protects its patients and consumers.

The public comment period is now closed.